soliris
Scope
Date
~
-
Bio & PharmaSamsung Bioepis leads in Soliris biosimilar market in Europe
STOCKHOLM – Samsung Bioepis Co.'s biosimilar to Soliris for the treatment of patients with rare, life-threatening disease paroxysmal nocturnal...
May 27, 2024 (Gmt+09:00)
-
Bio & PharmaSamsung Bioepis releases Soliris biosimilar in Europe
Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, is rolling out its latest product Epysqli,...
Oct 19, 2023 (Gmt+09:00)
-
Bio & PharmaSamsung Bioepis to enhance biosimilar presence with Epysqli
FRANKFURT – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is looking to gain ground in the ra...
Jun 12, 2023 (Gmt+09:00)
-
Bio & PharmaSamsung Bioepis gets approval to sell biosimilar in Europe
South Korea's Samsung Bioepis has received approval in Europe to sell a biosimilar of Soliris, a drug for the treatment of adult and children patien...
May 31, 2023 (Gmt+09:00)
-
Bio & PharmaSamsung Bioepis’ SB12 shows same clinical effects as Alexion’s Soliris
Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said its SB12, a proposed biosimilar to Alexion Pharmaceuticals Inc.’s rare bl...
Jun 14, 2022 (Gmt+09:00)
language
Latest News
- 1 NCSOFT invests in US game startup emptyvessel
- 2 Maybe Happy Ending: How a Seoul-made robot love story rewrote Broadway playbook
- 3 NPS yet to schedule external manager selection; PE firms’ fundraising woes deepen
- 4 Woori Financial wins approval for Tongyang, ABL Life acquisition
- 5 BMW surpasses Mercedes in Korean sales amid imported vehicle market shake-up
